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A B S T R A C T
Background
“Foot drop” or “Floppy foot drop” is the term commonly used to describe weakness or contracture of the muscles around the ankle
joint. It may arise from many neuromuscular diseases.
Objectives
To conduct a systematic review of randomised trials of treatment for footdrop resulting from neuromuscular disease.
Search strategy
We searched the Cochrane Neuromuscular Disease Group Trials Register (July 2005), MEDLINE (January 1966 to July 2005),
EMBASE (January 1980 to July 2005), AMED (January 1985 to July 2005) and CINAHL databases (January 1982 to July 2005).
Selection criteria
Randomised and quasi-randomised trials of physical, orthotic and surgical treatments for footdrop resulting from lower motor neuron
or muscle disease and related contractures were included. People with primary joint disease were excluded. Interventions included a
’wait and see’ approach, physiotherapy, orthotics, surgery and pharmacological therapy. The primary outcome measure was ability to
walk whilst secondary outcome measures included dorsiflexor torque and strength, measures of ’activity’ and ’participation’ and adverse
effects.
Data collection and analysis
Methodological quality was evaluated by two authors using the van Tulder criteria. Three studies with altogether 139 participants were
included in the review. Heterogeneity of the studies precluded pooling the data.
Main results
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Early surgery did not significantly affect walking speed in a trial including 20 children with Duchenne muscular dystrophy. After one
year, the mean difference (MD) of the 28 feet walking time was 0.00 seconds (95% confidence interval (CI) -0.83 to 0.83) and the
MD of the 150 feet walking time was -2.88 seconds, (95% CI -8.18 to 2.42). In a trial with altogether 26 participants with Charcot-
Marie-Tooth disease (hereditary motor and sensory neuropathy), long-term strength training significantly increased walking speed on
a 6 metre timed walk (MD -0.70 seconds, 95% CI -1.17 to -0.23) but not on a 50 metre timed walk (MD -1.9 seconds, 95% CI -
4.09 to 0.29). In a trial of a 24-week strength training programme in 28 participants with myotonic dystrophy, there was no significant
change in walking speed on either a 6 or 50 metre walk.
Authors’ conclusions
Using the primary outcome of ability to walk, only one study demonstrated a positive effect and that was an exercise programme for
people with Charcot-Marie-Tooth disease. Surgery was not significantly effective in children with Duchenne muscular dystrophy.More
evidence generated by methodologically sound trials is required.
P L A I N L A N G U A G E S U M M A R Y
Rehabilitation for foot drop (weakness or muscle shortening (contracture) at the ankle joint)
Foot drop is the term commonly used to describe weakness or contracture of the muscles at the ankle joint. It may arise from many
neuromuscular diseases. Interventions might include a ’wait and see’ approach, physiotherapy, orthotics (appliances), surgery or drug
therapy. The review identified three randomised controlled trials which met the criteria for inclusion in the review, involving 139
participants in total. In one trial involving people with Charcot-Marie-Tooth disease, also known as hereditary motor and sensory
neuropathy, exercise had a significant beneficial effect on walking ability. A trial of surgery on the Achilles tendon in boys withDuchenne
muscular dystrophy had no significant effect on walking ability. Data from a third trial of exercise in people with facioscapulohumeral
muscular dystrophy showed no positive effect on ankle strength. Further randomised controlled trials are needed.
B A C K G R O U N D
This Cochrane Review investigated the problem of weakness and
contracture of the muscles around the ankle joint, which arise
from neuromuscular diseases affecting the lower motor neuron
(LMN) or muscle. This condition is commonly called foot drop or
’floppy foot drop’ (Donaghy 2001). Foot drop canhave a profound
effect on gait. In moderate cases, the front of the foot drops to the
floor after heel strike, preventing the striding leg from swinging
through, while in severe cases toe strike may precede heel strike
and the toe may catch the ground during swing-through of the leg,
whichmay lead to tripping or falling. Using the terminology of the
International Classification of Function, Disability and Health (
WHO 2001), foot drop is thus an ’Impairment of Body Structure’
that may markedly influence the ’Activities’ and ’Participation’ of
the affected individual.
The major cause of foot drop is weakness of the muscles of ankle
dorsiflexion, primarily tibialis anterior, but with important contri-
butions from weakness of the long extensors of the toes (extensor
hallucis longus and extensor digitorum longus). A significant, sec-
ondary effect of this weakness is shortening and contracture of the
Achilles tendon, which is formed by the merging of the tendinous
portions of themajormuscles of plantar flexion, the gastrocnemius
and soleus. However, the ankle is a complex bipartite joint, able to
move in four directions: dorsiflexion, plantar flexion, eversion and
inversion. Many of the conditions which cause weakness of the
dorsiflexors, also affect the muscles of eversion (peroneus tertius
and peroneus longus) and inversion (tibialis posterior). The foot
drop syndrome therefore often also incorporates weakness of these
muscles, and associated contracture of their antagonist muscle ten-
dons. The exact contribution may differ between conditions.
This review, therefore, has greater clinical relevance if the term
Achilles tendon is seen as convenient shorthand for all the tendons
acting around the ankle joint, which may be involved when foot
drop occurs. Similarly we included research that describes weak-
ness of the other muscles which move the ankle, not only isolated
involvement of the dorsiflexion agonists, as long as the lower mo-
tor neuron was primarily affected. Conversely this review specifi-
cally excluded ankle weakness secondary to upper motor neuron
lesions, and soft tissue contractures associated with non-neurolog-
ical disease, such as arthritis or burns.
Aetiology of foot drop and contracture
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Floppy foot drop can result from damage to any part of the lower
motor neuron between the lumbosacral spine and the muscles of
ankle dorsiflexion. Classified anatomically, a non-exhaustive list
of the common causes would include:
• Anterior horn cell of the spinal cord (eg poliomyelitis
and motor neuron disease).
• Motor nerve root eg cauda equina lesions and involve-
ment of the lumbosacral nerve roots as they exit from
the spine, usually associatedwith intervertebral disc pro-
lapse.
• Peripheral motor nerve as part of a diffuse periph-
eral neuropathy (including Guillain-Barré syndrome,
chronic inflammatory demyelinating polyneuropathy).
• Hereditary motor and sensory neuropathy (for example
Charcot-Marie-Tooth disease).
• Involvement of specific peripheral nerves derived from
the sciatic plexus:
(a) the sciatic nerve as it passes from the pelvis through the sciatic
notch, past the hip joint and into the leg (eg with pelvic fractures,
buttock injections, and following pelvic surgery and hip replace-
ment).
(b) the peroneal nerve (which supplies all the evertors and dorsi-
flexors of the ankle), often as a result of lower limb fractures where
the nerve traverses the fibular head.
• Primary muscle disease eg muscular dystrophy (in-
cluding Duchenne, Becker, facioscapuloperoneal and
Emery-Dreifuss dystrophies).
Incidence and prevalence of foot drop
The incidence and prevalence is hard to establish. Geboers (
Geboers 2001a) suggested one new case per 6000 people each year,
based on referrals of newly affected patients to a Neurology and
Rehabilitation Service in Heerlen, Netherlands, serving an esti-
mated population of 300,000. As the majority of the cases had
either peroneal nerve palsy or prolapsed discs, and the referral rate
in the area was not known, this may well have been an underesti-
mate. Any neurological rehabilitation unit sees a significant num-
ber of affected patients annually.
Treatment modalities
Despite the frequency of foot drop, and the serious effect that it has
on gait and general function, the literature provides little direction
as to its treatment. Recent comprehensive textbooks on neurology
and neurorehabilitation tend to address the matter only briefly,
offering various therapeutic options in a non-critical way; thus ’it
is important to prevent contracture of the Achilles tendon, and
the foot should be splinted in dorsiflexion day and night, and the
ankle moved through its full range passively’ (Donaghy 2001).
Several therapeutic approaches are known to be used in practice in-
cluding ’wait and see’ (ie no intervention), physiotherapy, surgery
and drug treatment.
The authors could not locate any recent, formal review of this
topic in the published literature that critically compares these ap-
proaches. This review aims to fill this gap as a basis for making
clinical decisions, identifying the need for trials, and maintaining
an up to date record of such research in the future.
O B J E C T I V E S
The objective was to review systematically all randomised and
quasi-randomised trials of the treatment of foot drop resulting
from lower motor neuron or muscle disease, including the pre-
vention and treatment of Achilles tendon contracture, and other
soft tissue contractures that develop in association with such foot
drop.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) and quasi-
randomised trials of physical, orthotic and surgical approaches in
the treatment of lower motor neuron foot drop, and the preven-
tion and treatment of Achilles tendon contracture, and other soft
tissue contractures that develop in association with such foot drop.
Quasi-randomised trials are those trials in which treatment alloca-
tion was intended to be random, but might have been biased (eg
alternate allocation).
Types of participants
We included studies pertaining to participants of all ages who were
described as having:
• lower motor neuron or ’floppy’ foot drop, whether the
diagnosis was made clinically or through nerve conduc-
tion studies and EMG; and/or
• contractures of the Achilles tendon (or other associated
tendons) that had developed secondary to the foot drop,
and which affected the range of motion of the ankle.
We specifically excluded participants with primary joint or soft
tissue problems (eg arthritis or burns).
Types of interventions
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We included all therapeutic approaches known to be used in prac-
tice, whether used alone, or within the context of a multidisci-
plinary rehabilitation programme, ie:
• A non-interventionist approach based on the expecta-
tion either that recovery will occur equally well without
treatment or that the deficit does not warrant treatment,
at least at present.
• Physiotherapy, which may have several components:
(a) maintenance of passive range of motion;
(b) attempts to improve active muscle movement through isotonic
or isometric exercise (Germain 1995; Rozier 1979);
(c) attempts to improve activemusclemovement through electrical
nerve stimulation, often timed to occur during foot contact using a
switch (ie acting as an orthosis) and often referred to as Functional
Electrical Stimulation.
• Orthotics, used to splint the joint in a functional posi-
tion. At rest, these prevent the foot falling into a posi-
tion of forced plantar flexion (which could cause a con-
tracture with a major effect on gait); the risk of trip-
ping while walking is also minimised, with a positive
effect on patient safety. However, some debate has de-
veloped as to whether orthotics will enhance recovery
of the paretic muscle by facilitating walking, or retard
recovery through immobilisation and disuse atrophy (
Geboers 2001a; Geboers 2001b; Geboers 2002; Tropp
1995).
• Surgery of various types, including tendon lengthening
procedures and transfers (Wiesseman 1981), and other
orthopaedic interventions such as subtalar arthrode-
sis (Jaivin 1992). Surgical management of the primary
cause, such as lumbar disc surgery for prolapse or de-
compression of the peroneal nerve, is outside the scope
of this review.
• Pharmacological therapy was included as some modal-
ities (such as nerve growth factor administration) may
well become important in the future. However where
this has formed the topic for another Cochrane review,
the authors will defer to its content, rather than review-
ing the topic independently.
Types of outcome measures
The primary outcome measure that was considered was a test of
walking ability, using a validated objective test, limited either by
distance (eg the 10 metre test, with and without stairs) or time (eg
the six minute endurance test).
However we also included studies that based their findings on
other outcomemeasures provided theyweremeasured using a scale
validated in the relevant population, including:
• Active and passive range of motion of the ankle (mea-
sured using a goniometer or inclinometer);
• Dorsiflexor torque and strength;
• ’Activities’ (WHO2001)measuredwith validated tools,
and orientated to either personal Activities of Daily Liv-
ing (ADL) (eg the Barthel ADL Index), domestic or
community ADL;
• Measures of ’participation’ (WHO 2001): eg ability to
work;
• Quality of life.
• Cost effectiveness.
• Adverse effects attributable to the intervention eg ulcer-
ation preventing use of an orthodox device and falls.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Neuromuscular Disease Group Trials
register (searched July 2005), MEDLINE (from January 1966 to
July 2005), EMBASE (from January 1980 to July 2005),CINAHL
(from January 1982 to July 2005), AMED (from January 1985
to July 2005). The British Nursing Index and Royal College of
Nursing Journal of Databases was also studied (from January 1985
to July 2005).
The following search terms were used:
• foot drop OR floppy foot drop
• ankle contracture
• Achilles tendon contracture OR shortening
• exercise OR physiotherapy AND lower motor neuron
lesions
• orthotics AND lower motor neuron lesions
• nerve stimulation AND lower motor neuron lesions
• surgery AND lower motor neuron lesions
In the original protocol we proposed to contact authors, however
we were only able to contact Dr E van der Kooi and Dr E Linde-
man.
Searching other resources
See Appendix 1, Appendix 2, Appendix 3, Appendix 4 and
Appendix 5.
Data collection and analysis
Three authors checked the titles and abstracts of the articles iden-
tified by the search (CS, LTS, PD). The same authors extracted
data using a specially designed form, assessed the methodological
quality of the selected articles using a standardised grading system,
and independently decided upon inclusion (CS, LTS, PD). No
disagreement between authors was encountered.
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Selection of studies
Studies were included if:
• they were randomised or quasi-randomised.
• over 60% of participants included initially had follow
up data.
• the control group did not exercise the leg systematically.
Studies were excluded if:
• the study protocol was not adhered to.
• the groups varied greatly at entry (baseline) and there
was no statistical adjustment for this.
Assessment of methodological quality
Assessment of methodological quality using a standardised grad-
ing system is essential if the methodological quality of studies is
to be reviewed objectively. Many previous Cochrane reviews have
based their assessments on the three essential criteria described by
Jadad et al (Jadad 1996) including method of treatment alloca-
tion, whether trials have ensured an intention-to-treat analysis and
attempted concealment of allocation.
These criteria were developed for interventional trials of drug ther-
apy, but are less easy to apply to trials of rehabilitation interven-
tions where, as discussed by Turner-Stokes (Turner-Stokes 2005),
blinding of subjects and therapists is rarely possible as they are
aware of when treatment is being implemented and received. An
alternative checklist, the van Tulder scale was therefore employed
(van Tulder 1997). The scale includes the three Jadad criteria, but
adds further criteria to reach a total of nineteen (11 criteria for
internal validity, 6 descriptive criteria and 2 statistical criteria) (
Table 1). This approach was used for methodological evaluation
in this review, and on this basis an RCT was considered to be of
highmethodological quality if there were positive scores on at least
six out of eleven internal validity items, at least three out of six
descriptive items and at least one out of two statistical items.
Table 1. Scoring criteria using the method of van Tulder 1997
Criterion Score positive if:
Eligibility criteria specified A list of inclusion / exclusion criteria was explicitly stated.
Method of randomisation A random (unpredictable) assignment sequence was used.
Treatment allocation concealment Assignment was concealed from the investigators.
Similarity of baseline characteristics The study groups were comparable at baseline for the important prognostic param-
eters.
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Table 1. Scoring criteria using the method of van Tulder 1997 (Continued)
Intervention and control specifically described Details were given of the programme, including disciplines involved and treatment
duration.
Blinding of observers Observers were blinded regarding treatment allocation and standardised assessment
measures were used to structure the interviews. It was scored negative if only self-
reported (questionnaire) outcomes were used and no observer outcomes.
Co-interventions avoided or equal Co-interventions were avoided in the design of the study or were equally divided
among the intervention groups.
Compliance Compliance was measured and satisfactory in all study groups.
Outcome measures relevant Outcome measures reflected disability (activity) or participation as relevant to the
intervention.
Withdrawal rate acceptable The number of randomised patients minus the number of patients at the main
moment of effect measurement divided by all randomised patients and multiplied
by 100, was less than 20% for short-term outcomes or less than 30% for long-term
outcomes.
Short-term outcome measurement Outcomes were measured at the end of treatment (e.g. admission to discharge) or
within 6 months of the end of treatment.
Long-term outcome measurement Outcomes were measured at 1 year or more.
Intention-to-treat analysis All randomised patients were included in the analysis (minus missing values), irre-
spective of non-compliance and co-interventions. If loss to follow-up was substantial
(20% or more), an intention-to-treat analysis as well as an alternative analysis, which
accounts for missing values (e.g. a worst-case analysis), should have been performed.
Point estimates and measures of variability Amean or median figure was given for each important outcome parameter, together
with a measures of variability such as standard deviation, standard error of themean,
or 95% confidence intervals.
Blinding
In the rehabilitation context, it is seldom possible to blind either
participants or therapists to the therapeutic intervention.However
it is usually possible to blind the assessor.
Concealment of treatment allocation
Examples of ’adequate procedures’ for treatment allocation con-
cealment are:
• assignment of treatment at random by an independent person
not responsible for determining the eligibility of the participants.
• a centralised randomisation scheme - eg a computer system pro-
viding allocations in a locked, unreadable file that could be assessed
only after inputting the characteristics of an enrolled participant.
• numbered or coded containers, or sequentially numbered, sealed,
opaque envelopes.
If the concealment of treatment allocation was described only as
random or randomised, it was considered unclear.
Adverse effects
Adverse effects of rehabilitation are potentially possible, but are
considered infrequent by clinicians. The absence of adverse effects
is therefore seldom specifically recorded. Nonetheless we looked
for recording of adverse events.
Analysis and data synthesis
Meta-analysis can be undertaken only if the study populations,
interventions, outcomes and study designs are agreed to be suf-
ficiently consistent to allow pooling of data. There was, as will
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be seen, too much clinical heterogeneity among the studies with
regard to participants (diagnosis and severity of disease), interven-
tion (duration frequency and setting) and outcome measures (di-
versity of assessment tools) to make such analyses possible in this
review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Included studies
The total number of references the search yielded was as follows:
NMD Group specialised register 17 references, AMED 15 refer-
ences, CINAHL 52 references, EMBASE 44 references, MED-
LINE 17 references. The number studied in full text was 12. A
PhD thesis reporting a study published in two articles was not
reviewed separately. There was no disagreement between the two
authors in terms of the inclusion and exclusion of studies. Three
studies were included (reported in six publications), one includ-
ing boys with Duchenne muscular dystrophy, one adults with fa-
cioscapulohumeral muscular dystrophy and one with participants
who had either myotonic dystrophy or Charcot-Marie-Tooth dis-
ease, and the two groups have been discussed separately below.
Duchenne muscular dystrophy
Surgical intervention
Manzur 1992 studied the effects of surgical intervention in boys
with Duchenne muscular dystrophy (DMD). Participants, aged
four to six years, were randomised to either conservative treatment
or surgical intervention. Surgery used Rideau’s approach (Rideau
1986). This consists of open release at the hip of the sartorius mus-
cle, the superficial head of the rectus femorismuscle and tensor fas-
ciae lati. The Achilles tendon is lengthened and hamstring tendons
released if there are knee flexion contractures. Participants were
transferred to hospital after three days where they were mobilised
by physiotherapy between the third and sixth day after surgery.
They were discharged home four to six days following surgery,
walking without orthotic support, and without routine passive
stretching or physiotherapy. The control group continued with
regular passive stretching of the Achilles tendon, iliotibial bands
and hip flexors, performed daily by the parents after demonstra-
tion by the physiotherapist. All boys were assessed at three month
intervals in the first year, and twice annually thereafter.
Outcome evaluation was based on walking time over 28 and 150
feet, muscle strength (rated using the Medical Research Coun-
cil Scale (MRC 1943), myometry of five muscle groups in the
legs and two in the arms, the timing of Gowers’ manoeuvre, mo-
tor ability (based on 20 activities), measurement of contractures,
gait analysis, ultrasound of the quadriceps femoris muscle. Needle
muscle biopsy of the vastus lateralis muscle was carried out before
and after operation. Clinical photographs and video recordings of
movement quality were also taken.
Twenty-eight boys were assessed for recruitment. Eight were re-
jected. Three were too weak, two were unable to co-operate with
assessments, the parents of two boys refused consent and one had
experienced complications during previous surgery. Twenty boys
were therefore randomised into the two groups defined above (n =
10 in each group). Surgery was tolerated well in the surgical group
with all participants discharged within a week of surgery. The mo-
tor ability score and Medical Research Council Scale scores were
similar between the two groups at baseline. All participants were
followed up for a minimum of one year, the time used for follow-
up analysis. Four of the ten operated boys showed initial improve-
ment in qualitative gait analysis. This improvement was defined
by the authors as “particularly related to improved heel strike” and
was apparently “still noticeable up to a year after surgery”. Formal
gait analysis revealed no significant difference between the two
groups at one year on any of the six parameters studied (step and
stride length, swing phase duration, double support time, cadence
and velocity). No difference between groups was found in Med-
ical Research Council Scale score, myometry or Gower’s times at
follow-up.
Achilles tendon contractures were all severe in the surgical group
and were reduced by surgery from a mean of 26° to 16° at three
months. However, two of the ten boys developed contractures
again within one year of surgery. Iliotibial band contractures were
reduced from a mean of 6º to 1º at one year follow-up.
Ultrasound scanning of the muscles which was found to be ab-
normal in all participants before surgery, revealed no significant
change or differences between groups at one year follow-up.
At two years, five boys in the control group and six in the surgical
groupwere reassessed. Recurrences of Achilles tendon contractures
were noted in five of the six operated boys on at least one side.
One boy lost independent ambulation by 2.5 years after surgery.
The authors concluded that “there was no measurable difference
betweenour surgical and conservative groups andour study has not
shown any benefit of early surgery in relation to muscle strength
and function”. They noted that contractures could be reduced in
the short-term but recurred in at least seven of the 10 boys within
one to two years of surgery.
A long-term follow up of the same group of 20 boys a mean of
nine years after surgery was published as an abstract for the Fourth
International Congress of the World Muscular Dystrophy Soci-
ety in 1999, but the number of participants at follow up was not
specified. The follow-up revealed recurrence of contractures in all
boys in the surgical group and authors concluded that early limb
surgery demonstrated no functional benefit. The Rideau opera-
tion was not therefore recommended as routine treatment for this
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condition.
Facioscapulohumeral muscular dystrophy
Exercise and strength training
Moderate severe progressive strength training in participants with
facioscapulohumeral muscular dystrophy was studied by van der
Kooi 2004. Seventy participants with facioscapulohumeral mus-
cular dystrophy were randomly assigned either to a “training” or
“non training” group. The training group underwent moderate,
progressive strength training focusing on elbow flexors and ankle
dorsiflexors. Training consisted mainly of dynamic exercises car-
ried out at home three times a week for 26 weeks. Participants
were evaluated every third week for muscle strength (isometric,
sustained and dynamic). Muscle mass was also estimated using
computerised tomography.
The treatment group showed increases in all strength parameters
in comparison with the control group at the elbow but only in
isometric and sustained strength at the ankle. Statistical signifi-
cance was only found with respect to dynamic strength at the el-
bow (27% increase in training group versus 7% increase in control
group). No data were provided regarding the other outcomes.
The authors concluded that mainly dynamic strength training
could lead to very specific, moderate gains in dynamic strength
without any negative effects.
Participants were secondarily randomised at 26 weeks into one
of four groups: training or non-training with either albuterol or
placebo for a subsequent 26weeks. The final assessment took place
at 52 weeks from when the initial training began. Regardless of
drug status training did not improve static strength of the elbow
flexors (maximum voluntary isometric strength and 30 second
sustained isometric strength). However, dynamic strength did im-
prove in comparison to the non-training group (“1-repetitivemax-
imum”). All strength measurements for elbow flexors increased
significantly in the albuterol treatment groups compared to the
placebo groups. Ankle dorsiflexor strength did not appear to be
improved by either training or the use of albuterol, alone or in
combination and showed a decrease of 8 to 28% in all groups. The
authors concluded that the use of albuterol can induce moderate
strength gains in addition to the findings of the preceding study.
Myotonic dystrophy
Exercise and strength training
Strength training was also studied in participants with myotonic
dystrophy by Lindeman 1995. Patients living within 100 km of
Maastricht between the age of 16 and 60 years were recruited
and subjected to a “qualification period” to establish their suit-
ability for the trial, and provide them with the information nec-
essary for them to consent. Participants were excluded based on
any contraindications to muscle strengthening exercises or other
unrelated disabling conditions that could influence the scoring.
Thirty-three participants were individually matched on the basis
of muscle strength and performance on a stair-climbing test be-
fore being randomly assigned to a training or control group. The
treatment group carried out home based knee extension and flex-
ion, and hip extension and abduction weight exercises three times
a week for 24 weeks, completing a training diary over the course
of the programme. Training was progressive over the course of
the 24-week programme. Over the first eight weeks participants
carried out three sets of 25 repetitions at 60% of one maximum
repetition (1RM). From the ninth to the sixteenth week, intensity
was increased to three sets of fifteen repetitions at 70 % of 1RM,
and during the final eight week period, the intensity progressed
further to three sets of ten repetitions at 80 % of 1RM. Outcome
assessments were carried out after eight, sixteen and 24 weeks by
an observer blinded to treatment allocation. Outcome measures
used included isokinetic and isometric muscle strength and en-
durance (using a CYBEX Dynamometer), and functional perfor-
mance based on stair climbing, rising from a chair or from supine,
and walking 6 and 50 metres. In addition participants completed
the Western Ontario & MacMaster University Osteoarthritis In-
dex (WOMAC) and the Sickness Impact Profile (SIP). Partici-
pants also scored their difficulty in performing life activities on
a Visual Analogue Scale. Finally they were asked to identify the
“disease related problems they faced in daily life” using a question-
naire adapted from the “Problem Elicitation Technique” (PET).
Compliance with therapy was high and a low drop out rate was
observed. With respect to physical functional abilities, there was
no significant change in stair climbing, rising from a chair or
from supine position, or walking six or 50 metres. Based on
the WOMAC, statistically significant improvement was found in
standing, getting into and out of a car and putting on socks.
Using the Problem Elicitation Technique scale, most of the hin-
drances reported concerned activities that participants believed
were due to impaired leg function. In the treatment group, four
out of fifteen participants reported they could perform more ac-
tivities, whilst one reported a decrease in capacity to do so. In the
control group four out of eighteen reported a decrease and only
one reported an increase in the ability to perform activities. How-
ever, no statistically significant change was found.
Based on the “global assessment” the training group showed sig-
nificant improvement compared with controls in the responses to
the questions: “How were your complaints last week” and “I am
less hindered in daily activities because of my strength reduction.
Sixty-four per cent of the training group felt they had derived ben-
efit from the intervention.
With respect to strength, there was no significant change in knee
torque or endurance although a small non-significant training ef-
fect was observed in individuals in the training group who had
higher baseline strength. This is thought to be due to a higher
potential for strength increase in the stronger individuals. The
training group also increased in strength endurance compared to
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a decrease in the control group. However, these differences were
non-significant.
Only one participant experienced adverse effects in the form of
muscle pain and transient strength reduction. The authors suggest
that as no adverse effects were observed as a result of the training,
a more intense workload should be investigated in a similar pop-
ulation in future studies.
Peripheral neuropathy
Exercise and strength training
A muscle strengthening exercise programme was evaluated in par-
ticipants with Charcot-Marie-Tooth disease (Types 1 or 2) in con-
junction with the exercise programme carried out with people
with myotonic dystrophy described previously (Lindeman 1995).
Twenty-nine participants (21 with Charcot-Marie-Tooth disease
type 1, six with type 2, and two with unknown type) were indi-
vidually matched based on muscle strength and performance on
a stair-climbing test. Within each matched pair, participants were
randomly assigned to a training or control group. Outcome mea-
sures and the training group’s intervention were identical to those
outlined in the previous study.
Compliance with therapy was high and a low drop-out rate was
observed.
• Six metre walk time decreased significantly in the train-
ing group compared to the control group (P = 0.01).
• With respect to functional abilities on the WOMAC,
significant changes were found in stair climbing, rising
from a chair, getting into and out of a car, putting on
socks and lying down on the bed.
• From the Problem Elicitation Technique, in the treat-
ment group7out of 15participants could performmore
activities as a result of training, whereas two reported a
decrease in capacity to do so. In the control group 2 out
of 13 participants reported a decrease in activities, and
none reported an increase.
• No significant changes were found in the ”global assess-
ment“. However, 93% of the participants felt they had
derived benefit from the intervention.
• Isokinetic knee extension torque increased significantly
in the training group (14%, P < 0.005) and flex-
ion torque increased but without statistical significance
(13%, P = 0.07).
Two participants experienced adverse effects in the form of muscle
pain and transient strength reduction. The authors suggest that as
minimal adverse effects were observed as a result of the training, a
more intense workload could be investigated in a similar popula-
tion in future studies.
Risk of bias in included studies
Details of the methodological quality of the included studies are
described in the ’Characteristics of included studies’ table, Table 2
andTable 3. All studies were rated using the vanTulder (van Tulder
1997) scale of methodological quality. Studies were included if
they fulfilled the criteria specified above.
Table 2. Methodological Quality assessed by the van Tulder Method
Study ID Internal validity Descriptive criteria Statistical Criteria High Quality
Manzur 1992 5 4 2 High quality for descriptive criteria only
Lindeman 1995 8 5 1 High for internal validity & descriptive cri-
teria
Van der Kooi 2004 9 6 2 High qulity for all criteria
Manzur 1992
Details of randomisation were not explicit stating only that partic-
ipants were randomised into groups. No details of allocation con-
cealment were provided. In addition blinding of outcome asses-
sors was not carried out. However, withdrawal and drop-outs were
described and acceptable and follow-up measures were carried out
at short and long-term. Intention-to-treat analysis was also carried
out.
van der Kooi 2004
In the van der Kooi 2004 study, participants were randomly as-
signed either to a ”training“ or ”non-training“ group and again
into drug treatment groups, although no further details on the
randomisation methods were provided. There was no evidence of
allocation concealment. Participants and therapists were blinded
to the drug treatment, as were assessors to all interventions. In
addition, withdrawals and drop-outs were described and accept-
able and short-term and long-term follow up measures were per-
formed. Intention-to treat analysis was also carried out.
Lindeman 1995
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In the Lindeman 1995 study, participants were individually
matched into pairs on the basis of muscle strength and perfor-
mance on a stair-climbing test. Within each matched pair partic-
ipants were randomly assigned to a training or control group. Al-
though treatment allocation was not concealed during randomi-
sation, assessors were blinded to treatment allocation. This was
monitored and results revealed assessors were aware of participants’
group in only 20% of cases. Withdrawal and dropouts were de-
scribed and acceptable and follow-up measures were performed at
both short and long-term stages.
Effects of interventions
Duchenne muscular dystrophy
Primary outcome measure: Walking ability using a validated
objective test
In theManzur 1992 trial with 20 participants, at one year, ”Early“
surgery did not improve 28 feet or 150 feet walking times. The
mean walking speeds (in seconds) increased by 0.3 and 1.3 (re-
spectively) in the control group (n = 10) and 0.8 and 4.1 in the
surgery group (n = 10). The mean difference (MD) for walking
time for 28 feet was 0.00 seconds, 95% confidence interval (CI)
-0.83 to 0.83 (see Analysis 01.01) and for 150 ft was -2.88, 95%
CI -8.18 to 2.42 (see Analysis 01.02). At two years the data for
150ft walking speed were only available for control and surgery
participants. Two boys (out of three) deteriorated rapidly in the
second year post surgery. The data were not available at the 9 year
follow up (Manzur 1992).
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity measures, participation
measures, QOL, cost effectiveness and adverse effects
For the secondary measures, ”early“ surgery did not have a sig-
nificant effect on muscle strength measured by mean kg force of
6 lower limb muscle groups. Strength decreased by 0.7 kg force
in the control group and 0.7 kg force in the surgery group (MD
0.0 kg force, 95% CI -0.55 to 0.55 secs) (see Analysis 01.04). At
one year after randomisation no significant difference in ”motor
ability score“ was seen. The mean change was -1 in the control,
and -2 in the surgery group, MD 1 (motor ability score 0 to 40)
95% CI -1.08 to 3.08 (see Analysis 01.03). ’No benefit’ was re-
ported at nine years. Surgery appeared to have a positive effect on
contractures in the short-term, with a mean increase in control
group of 3º and mean decrease of 7.5º in the surgery group. At 2
years, 5 of 6 operated boys had recurrence of contracture and all
(number not given) had recurrence at 9 years (Manzur 1992).
Facioscapulohumeral muscular dystrophy
Primary outcome measure: Walking ability using a validated
objective test
Data for this outcome were not available.
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity measures, participation
measures, QOL, cost effectiveness and adverse effects
In one trial with altogether 65 participants (van der Kooi 2004),
there was a decrease in strength at ankle dorsiflexion in both the
training and non-training groups but without any significant dif-
ference between the two groups (isometric strength MD -0.43,
95% CI -2.48 to 1.62 KgF; dynamic strength MD 0.44, 95%
CI -0.89 to 1.77 KgF, see Analyses 02.01 and 02.02). By contrast
there was an increase in the strength of the other exercised muscle
group, elbow flexion, which was not the topic of this review.
Myotonic dystrophy
Primary outcome measure: Walking ability using a validated
objective test
In a trial with 28 participants, there was no significant change in
mean walking speed over six or 50 metres following a 24-week
strength training programme (Lindeman 1995). The mean in-
crease was 0.5 and 3.5 seconds respectively in the control group
and 0.3 and 2.7 seconds in the training group. Over 6 metres, the
MD was 0.20 seconds, 95% CI -0.39 to 0.79 (see Analysis 03.01)
and over 50 metres the MD was 0.80 seconds, 95% CI -3.69 to
5.29 (see Analysis 03.02).
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity measures, participation
measures, QOL, cost effectiveness and adverse effects
The same study demonstrated no significant change in time taken
(in seconds) for climbing stairs, descending from stairs, rising from
a chair or standing from lying supine (see Analysis 03.03). There
was statistically significant improvement in self report of ease of
standing, getting into and out of a car and putting on socks, but
the numerical results were not provided. Only one participant
experienced adverse effects, which consisted of muscle pain and
transient strength reduction.
Charcot-Marie-Tooth disease
Primary outcome measure: Walking ability using a validated
objective test
In a trial with 26 participants, the mean six metre walking speed
improved significantly following a 24-week strength training pro-
gramme (Lindeman 1995). The walking time decreased by 1.0
seconds in the exercised group and 0.3 seconds in the control
group, MD -0.70 seconds, 95% CI -1.17 to -0.23 (see Analysis
04.01). A significant difference was not seen in the 50 metre timed
walk. The exercised group decreased by an average of 2.2 seconds
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and the control group by 0.3 seconds, MD -1.9 seconds, 95% CI
-4.09 to 0.29 (see Analysis 04.02).
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity measures, participation
measures, QOL, cost effectiveness and adverse effects
The training programme led to no significant change in time taken
for climbing stairs, descending from stairs, rising from a chair
or standing from lying supine (see Analysis 04.03). There was a
significant improvement in self reported stair climbing, rising from
a chair, getting into and out of a car, putting on socks and lying
down on the bed, but the numerical results were not provided.
Two participants experienced adverse effects, ie muscle pain and
transient strength reduction.
Subgroup analysis
Insufficient data were available to allow us to compare interven-
tions in the common aetiological subgroups proposed in the pro-
tocol.
D I S C U S S I O N
The review provides little evidence to support any intervention
for treating foot drop in terms of improving walking or secondary
outcomes. The differences in patient condition and outcomemea-
sures between studies made meta-analysis impossible and made it
difficult to present firm conclusions from the review. In addition,
many of the studies examined were excluded due to insufficient
methodological quality which substantially reduced the body of
evidence.
Duchenne muscular dystrophy
There is some evidence that early surgery intervention is not ef-
fective in people with Duchenne muscular dystrophy in terms of
walking speed, muscle strength or other measures of functional
’motor ability’ at one, two or nine years after surgery. Surgery ap-
peared to have a positive effect on contractures in the short-term
although no long-term advantage was observed (Manzur 1992)
and the long-term risk of surgery increasing disability has not been
assessed.
Facioscapulohumeral muscular dystrophy
A six-week strength training programme of the ankle flexors failed
to show any increase in strength in participants with facioscapu-
lohumeral muscular dystrophy (van der Kooi 2004). However, it
was well tolerated with no reported adverse events. Nomeasures of
functionality were carried out making it impossible to draw con-
clusions about the effects of interventions on functional activities.
Myotonic dystrophy
A 24-week strength training programme was found to have no
effect on walking speed or the time taken to complete functional
tasks (Lindeman 1995). Participants reported ease of standing,
getting into and out of a car and putting on socks, but numerical
data are not presented.
Charcot-Marie-Tooth disease
A 24-week strength training programme was found to improve
walking speed but led to no significant change in time taken (in
seconds) for climbing stairs, descending from stairs, rising from a
chair or standing from lying supine (Lindeman 1995). Participants
reported improvement in functional tasks such as rising from a
chair, getting into and out of a car, putting on socks and lying
down on the bed, but no numerical results were presented.
Excluded studies
Most of the studies were excluded because of methodological inad-
equacies (not randomised or fatal flaws such as drop outs exceed-
ing 40%) and/or did not use an outcome specified in the review.
A non-randomised study (without masked assessment) by Forst
1999 described the long-term outcome of 213 participants with
Duchenne muscular dystrophy 87 of whom had surgery. They
concluded that the operation delayed the loss of independent am-
bulation by 1.25 years, and change in strength did not differ be-
tween groups. However, the baseline characteristics of the two
groups were not reported. In a randomised study of 27 boys with
Duchenne muscular dystrophyHyde 2000 investigated the effects
of wearing night splints on contractures and concluded that the
treatment group had a statistically significant annual delay of 23%
in the development of contractures compared to the control group.
However, the study was categorised as fatally flawed because the
number of drop-outs was excessive (9 of 15, 60% in the interven-
tion group). The effect of an ankle-foot orthosis on the strength
of paretic dorsiflexors was investigated in a non-randomised study
of 26 people with foot drop secondary to peroneal neuropathy
or L5 radiculopathy of six weeks to twelve months duration by
Geboers 2001a. The authors concluded that ankle-foot-orthosis
did not influence the restoration of strength in participants with
recent peripheral paralysis, but did not adversely influence recov-
ery. Additionally, the authors stated that the decrease in strength
observed in the healthy side of participants may be attributable to
an overall loss of strength due to a decrease in activity.
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The review covered a broad population of participants of all ages.
All studies involving participants described as having lower mo-
tor neuron or floppy foot drop and contractures of tendons that
develop secondary to foot drop affecting ankle range of motion
were included in the review. The wide range of patient character-
istics, incomparable outcome measures and poor methodological
quality made it difficult to carry out any meta-analysis which in
turn made it difficult to draw hard conclusions from the review.
Exercise intervention is well tolerated and without adverse effect
and may have a positive effect particularly in those with Charcot-
Marie-Tooth disease. However strong evidence is lacking and fur-
ther studies to support these findings would be beneficial. Early
surgery was also shown to have few benefits for children with
Duchenne muscular dystrophy and the long term risks have not
been assessed.
Limitations of this review
This review is subject to various limitations. First, our search may
have missed some relevant studies. The terms we used to identify
the groups of participants studied are imprecise, and it is possible
that studies may have been undertaken and reported using other
terms or simply giving the underlying disease (e.g. poliomyelitis)
on the grounds that there would be no clinical need to specify that
there was a floppy foot drop. However searching for studies on
the treatment (e.g. orthoses) would have identified many studies
investigating foot drop due to uppermotor neuron lesions, or joint
pathology.
Second, the reviewwas based on the assumption that rehabilitation
treatments for foot-drop where there was reduced muscle strength
and no increase inmuscle tone could be considered as being similar
in their effects and side-effects. However this may not be the case.
For example it is possible thatmuscle strengthening exercises could
be beneficial in people with disease of the lower motor neurone
but harmful in people with disease of the muscle itself. In fact the
evidence would suggest that this is not the case, but there may be
other examples where there is a differential effect.
Third, the choice of primary outcome measure (quantitative mea-
sures of walking performance) was based on the assumption that
walking speed would correlate with performance in most other ac-
tivities involving mobility. The results in at least one of the studies
suggests that this may not be true, and that it may not be sensible
in future to focus on walking speed. The alternative is to ask about
a range of specific activities that depend upon aspects of mobility,
investigating which activities are helped by any specific treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from one trial suggests that exercise is not detrimental
and may benefit the ability to walk in Charcot-Marie-Tooth dis-
ease. Limited evidence from one randomised trial showed no sig-
nificant benefit from early surgery to lengthen the Achilles tendon
inDuchenne muscular dystrophy on walking ability after one, two
or nine years. There have been no randomised trials to investigate
the efficacy of ankle foot orthoses for foot drop. Future studies and
future versions of this review should include outcome measures
which assess function such as measures of activities of daily living
and gait.
Implications for research
Exercise regimens of varying intensity and frequency have pro-
vided some evidence of benefit and should be evaluated in more
detail in the future. The use of orthotics on function and physio-
logical cost would be worthy of investigation. In addition the cost
effectiveness of such interventions should be investigated. Future
studies should include outcome measures which assess function
such as measures of activities of daily living. This would allow
readers to assess the influence of interventions on everyday life and
not concentrate purely on factors such as strength and range of
motion. It is important to link changes in strength and range of
motion with actual functionality.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Lindeman 1995
Methods RCT of matched pairs (matching on muscle strength)
Participants Participants with myotonic dystrophy or Charcot-Marie-Tooth disease (CMT).
Interventions Exercise (n = 14 MyD and n = 13 CMT) versus no exercise (n = 14 MyD and n = 13 CMT).
Outcomes Muscle strength and endurance, walking, stairs, WOMAC, SIP, VAS (life activities).
Notes Statistical change only in walking in CMT: trends to positive effect in all parameters.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Manzur 1992
Methods Unblinded RCT
Participants Boys aged 4 to 6 years with Duchenne muscular dystrophy.
Interventions Surgical (n = 10) versus conservative treatment (n = 10).
Outcomes Muscle strength, walking, Gower’s time, contracture measurement, motor activities.
Notes No difference in outcome at 1 year.
Follow up study in 1999, No difference in outcome at 8 to 11 yrs.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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van der Kooi 2004
Methods Unblinded RCT (two stage)
Participants Participants with facioscapulohumeral muscular dystrophy.
Interventions Strength training (n = 34) versus no training (n = 31): second randomisation at 26/52 into albuterol vs
no drug treatment.
Outcomes Muscle strength in legs and arms and muscle mass at 6 weeks.
Muscle strength in legs and arms at 1 year.
Notes At 6 weeks, training led to increased strength: statistically significant only at elbow.
At 1 year, training led to increased dynamic of elbow; albuterol increased elbow flexion: ankle dorsiflexion
deteriorated .
Published abstracts of both parts of the study van der Kooi 2000 and van der Kooi 2001.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
RCT - randomised controlled trial
MyD - myotonic dystrophy
WOMAC - Western Ontario and McMaster University Osteoarthritis Index
SIP - Sickness Impact Profile
VAS - Visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Forst 1995 Not randomised, compared with ’natural history’ cohort.
Forst 1999 Not randomised, compared with ’natural history’ cohort.
Geboers 2001a Not randomised, if alternative allocation on enrolment was used there would not be a 4 person difference between
groups at entry (11,15). Assessment not masked. No allocation concealment. Large between group difference in
mean age at entry (42 versus 60 years).
Geboers 2001b Same as Geboers 2001a and Geboers2002.
Geboers 2002 Same study as 2001a, compliance not reported for follow up data.
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(Continued)
Hyde 2000 Drop out rate, 9 of 15 in intervention, 7 of 12 in ’control’, total 16 of 27.
Richardson 2001 Did not use the specified outcome measures. Foot drop not diagnosed, paper talks about ’subclinical motor
involvement’.
Wiesinger 1998 Not foot drop
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D A T A A N D A N A L Y S E S
Comparison 1. Early surgery vs control in Duchenne Muscular Dystrophy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in 28ft walking speed in
seconds
1 20 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Change in 150ft walking speed
in seconds
1 20 Mean Difference (IV, Fixed, 95% CI) -2.88 [-8.18, 2.42]
3 Change in motor ability score
(min 0 max 40)
1 20 Mean Difference (IV, Fixed, 95% CI) 1.0 [-1.08, 3.08]
4 Change in combined strength of
6 lower limb muscle groups in
kilogram force
1 20 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 2. Strength training versus control in FSHD
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in muscle strength of
ankle dorsiflexors - maximum
voluntary isometric contraction
in kilogram force
1 65 Mean Difference (IV, Fixed, 95% CI) -0.43 [-2.48, 1.62]
2 Change in muscle strength ankle
dorsiflexors - dynamic strength
in kilograms
1 65 Mean Difference (IV, Fixed, 95% CI) 0.44 [-0.89, 1.77]
Comparison 3. Strength training vs control in Myotonic Dystrophy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Decrease in time to walk 6m
comfortably in seconds
1 28 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.39, 0.79]
2 Decrease in time to walk 50m,
fast in seconds
1 28 Mean Difference (IV, Fixed, 95% CI) 0.80 [-3.69, 5.29]
3 Change in time spent to achieve
mobility activities in seconds
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Descending stairs 1 28 Mean Difference (IV, Fixed, 95% CI) -2.0 [-6.22, 2.22]
3.2 Climbing stairs 1 28 Mean Difference (IV, Fixed, 95% CI) -0.8 [-3.98, 2.38]
3.3 Standing up from a chair 1 28 Mean Difference (IV, Fixed, 95% CI) -1.0 [-3.14, 1.14]
18Rehabilitation interventions for foot drop in neuromuscular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.4 Standing up from lying
supine
1 28 Mean Difference (IV, Fixed, 95% CI) 0.9 [-0.47, 2.27]
Comparison 4. Strength training vs control in Charcot-Marie-Tooth disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Decrease in time to walk 6m
comfortably (seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) -0.7 [-1.17, -0.23]
2 Decrease in time to walk 50m
fast walk (seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) -1.90 [-4.09, 0.29]
3 Change in time spent to achieve
mobility activities (seconds)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Descending stairs 1 26 Mean Difference (IV, Fixed, 95% CI) -0.79 [-1.95, 0.37]
3.2 Climbing stairs 1 26 Mean Difference (IV, Fixed, 95% CI) -0.71 [-1.71, 0.29]
3.3 Standing up from a chair
(seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.47, 0.17]
3.4 standing up from lying
supine (seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) -0.2 [-0.62, 0.22]
Analysis 1.1. Comparison 1 Early surgery vs control in Duchenne Muscular Dystrophy, Outcome 1 Change
in 28ft walking speed in seconds.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery vs control in Duchenne Muscular Dystrophy
Outcome: 1 Change in 28ft walking speed in seconds
Study or subgroup control treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 -0.1 (0.95) 10 -0.1 (0.95) 100.0 % 0.0 [ -0.83, 0.83 ]
Total (95% CI) 10 10 100.0 % 0.0 [ -0.83, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-1 -0.5 0 0.5 1
Favours control Favours treatment
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Analysis 1.2. Comparison 1 Early surgery vs control in Duchenne Muscular Dystrophy, Outcome 2 Change
in 150ft walking speed in seconds.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery vs control in Duchenne Muscular Dystrophy
Outcome: 2 Change in 150ft walking speed in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 -4.1 (6.64) 10 -1.22 (5.38) 100.0 % -2.88 [ -8.18, 2.42 ]
Total (95% CI) 10 10 100.0 % -2.88 [ -8.18, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
-10 -5 0 5 10
Favours control Favours treatment
Analysis 1.3. Comparison 1 Early surgery vs control in Duchenne Muscular Dystrophy, Outcome 3 Change
in motor ability score (min 0 max 40).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery vs control in Duchenne Muscular Dystrophy
Outcome: 3 Change in motor ability score (min 0 max 40)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 2 (2.21) 10 1 (2.53) 100.0 % 1.00 [ -1.08, 3.08 ]
Total (95% CI) 10 10 100.0 % 1.00 [ -1.08, 3.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
-4 -2 0 2 4
Favours control Favours treatment
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Analysis 1.4. Comparison 1 Early surgery vs control in Duchenne Muscular Dystrophy, Outcome 4 Change
in combined strength of 6 lower limb muscle groups in kilogram force.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery vs control in Duchenne Muscular Dystrophy
Outcome: 4 Change in combined strength of 6 lower limb muscle groups in kilogram force
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 0.7 (0.63) 10 0.7 (0.63) 100.0 % 0.0 [ -0.55, 0.55 ]
Total (95% CI) 10 10 100.0 % 0.0 [ -0.55, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-1 -0.5 0 0.5 1
Favours control Favours treatment
Analysis 2.1. Comparison 2 Strength training versus control in FSHD, Outcome 1 Change in muscle
strength of ankle dorsiflexors - maximum voluntary isometric contraction in kilogram force.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 1 Change in muscle strength of ankle dorsiflexors - maximum voluntary isometric contraction in kilogram force
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 31 -1.56 (4.16) 34 -1.13 (4.28) 100.0 % -0.43 [ -2.48, 1.62 ]
Total (95% CI) 31 34 100.0 % -0.43 [ -2.48, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
-4 -2 0 2 4
Favours control Favours treatment
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Analysis 2.2. Comparison 2 Strength training versus control in FSHD, Outcome 2 Change in muscle
strength ankle dorsiflexors - dynamic strength in kilograms.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 2 Change in muscle strength ankle dorsiflexors - dynamic strength in kilograms
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 31 -1.06 (2.78) 34 -1.5 (2.68) 100.0 % 0.44 [ -0.89, 1.77 ]
Total (95% CI) 31 34 100.0 % 0.44 [ -0.89, 1.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
-4 -2 0 2 4
Favours control Favours treatment
Analysis 3.1. Comparison 3 Strength training vs control in Myotonic Dystrophy, Outcome 1 Decrease in
time to walk 6m comfortably in seconds.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 1 Decrease in time to walk 6m comfortably in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 14 0.5 (0.8) 14 0.3 (0.8) 100.0 % 0.20 [ -0.39, 0.79 ]
Total (95% CI) 14 14 100.0 % 0.20 [ -0.39, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
-1 -0.5 0 0.5 1
Favours control Favours treatment
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Analysis 3.2. Comparison 3 Strength training vs control in Myotonic Dystrophy, Outcome 2 Decrease in
time to walk 50m, fast in seconds.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 2 Decrease in time to walk 50m, fast in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 14 3.5 (5.8) 14 2.7 (6.3) 100.0 % 0.80 [ -3.69, 5.29 ]
Total (95% CI) 14 14 100.0 % 0.80 [ -3.69, 5.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
-4 -2 0 2 4
Favours control Favours Treatment
Analysis 3.3. Comparison 3 Strength training vs control in Myotonic Dystrophy, Outcome 3 Change in time
spent to achieve mobility activities in seconds.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 3 Change in time spent to achieve mobility activities in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Descending stairs
Lindeman 1995 14 0.5 (3.6) 14 2.5 (7.2) 100.0 % -2.00 [ -6.22, 2.22 ]
Subtotal (95% CI) 14 14 100.0 % -2.00 [ -6.22, 2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
2 Climbing stairs
Lindeman 1995 14 0.3 (1.8) 14 1.1 (5.8) 100.0 % -0.80 [ -3.98, 2.38 ]
Subtotal (95% CI) 14 14 100.0 % -0.80 [ -3.98, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 Standing up from a chair
Lindeman 1995 14 0.2 (0.8) 14 1.2 (4) 100.0 % -1.00 [ -3.14, 1.14 ]
Subtotal (95% CI) 14 14 100.0 % -1.00 [ -3.14, 1.14 ]
-10 -5 0 5 10
Favours control Favours treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 Standing up from lying supine
Lindeman 1995 14 0.5 (2.2) 14 -0.4 (1.4) 100.0 % 0.90 [ -0.47, 2.27 ]
Subtotal (95% CI) 14 14 100.0 % 0.90 [ -0.47, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 3.59, df = 3 (P = 0.31), I2 =17%
-10 -5 0 5 10
Favours control Favours treatment
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 3 Change in time spent to achieve mobility activities in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Descending stairs
Lindeman 1995 14 0.5 (3.6) 14 2.5 (7.2) 100.0 % -2.00 [ -6.22, 2.22 ]
Subtotal (95% CI) 14 14 100.0 % -2.00 [ -6.22, 2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
-10 -5 0 5 10
Favours control Favours treatment
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Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 3 Change in time spent to achieve mobility activities in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 Climbing stairs
Lindeman 1995 14 0.3 (1.8) 14 1.1 (5.8) 100.0 % -0.80 [ -3.98, 2.38 ]
Subtotal (95% CI) 14 14 100.0 % -0.80 [ -3.98, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
-10 -5 0 5 10
Favours control Favours treatment
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 3 Change in time spent to achieve mobility activities in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 Standing up from a chair
Lindeman 1995 14 0.2 (0.8) 14 1.2 (4) 100.0 % -1.00 [ -3.14, 1.14 ]
Subtotal (95% CI) 14 14 100.0 % -1.00 [ -3.14, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
-10 -5 0 5 10
Favours control Favours treatment
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Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training vs control in Myotonic Dystrophy
Outcome: 3 Change in time spent to achieve mobility activities in seconds
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
4 Standing up from lying supine
Lindeman 1995 14 0.5 (2.2) 14 -0.4 (1.4) 100.0 % 0.90 [ -0.47, 2.27 ]
Subtotal (95% CI) 14 14 100.0 % 0.90 [ -0.47, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
-10 -5 0 5 10
Favours control Favours treatment
Analysis 4.1. Comparison 4 Strength training vs control in Charcot-Marie-Tooth disease, Outcome 1
Decrease in time to walk 6m comfortably (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 1 Decrease in time to walk 6m comfortably (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 13 0.3 (0.7) 13 1 (0.5) 100.0 % -0.70 [ -1.17, -0.23 ]
Total (95% CI) 13 13 100.0 % -0.70 [ -1.17, -0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0033)
-4 -2 0 2 4
Favours treatment Favours control
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Analysis 4.2. Comparison 4 Strength training vs control in Charcot-Marie-Tooth disease, Outcome 2
Decrease in time to walk 50m fast walk (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 2 Decrease in time to walk 50m fast walk (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 13 0.3 (2.9) 13 2.2 (2.8) 100.0 % -1.90 [ -4.09, 0.29 ]
Total (95% CI) 13 13 100.0 % -1.90 [ -4.09, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
-4 -2 0 2 4
Favours treatment Favours control
Analysis 4.3. Comparison 4 Strength training vs control in Charcot-Marie-Tooth disease, Outcome 3
Change in time spent to achieve mobility activities (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 3 Change in time spent to achieve mobility activities (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Descending stairs
Lindeman 1995 13 -0.09 (1.3) 13 0.7 (1.7) 100.0 % -0.79 [ -1.95, 0.37 ]
Subtotal (95% CI) 13 13 100.0 % -0.79 [ -1.95, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 Climbing stairs
Lindeman 1995 13 -0.01 (1.2) 13 0.7 (1.4) 100.0 % -0.71 [ -1.71, 0.29 ]
Subtotal (95% CI) 13 13 100.0 % -0.71 [ -1.71, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
3 Standing up from a chair (seconds)
Lindeman 1995 13 0.05 (0.3) 13 0.2 (0.5) 100.0 % -0.15 [ -0.47, 0.17 ]
-4 -2 0 2 4
Favours control Favours treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 13 13 100.0 % -0.15 [ -0.47, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
4 standing up from lying supine (seconds)
Lindeman 1995 13 0.1 (0.5) 13 0.3 (0.6) 100.0 % -0.20 [ -0.62, 0.22 ]
Subtotal (95% CI) 13 13 100.0 % -0.20 [ -0.62, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 2.03, df = 3 (P = 0.57), I2 =0.0%
-4 -2 0 2 4
Favours control Favours treatment
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 3 Change in time spent to achieve mobility activities (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Descending stairs
Lindeman 1995 13 -0.09 (1.3) 13 0.7 (1.7) 100.0 % -0.79 [ -1.95, 0.37 ]
Subtotal (95% CI) 13 13 100.0 % -0.79 [ -1.95, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
-4 -2 0 2 4
Favours control Favours treatment
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Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 3 Change in time spent to achieve mobility activities (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 Climbing stairs
Lindeman 1995 13 -0.01 (1.2) 13 0.7 (1.4) 100.0 % -0.71 [ -1.71, 0.29 ]
Subtotal (95% CI) 13 13 100.0 % -0.71 [ -1.71, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
-4 -2 0 2 4
Favours control Favours treatment
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 3 Change in time spent to achieve mobility activities (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 Standing up from a chair (seconds)
Lindeman 1995 13 0.05 (0.3) 13 0.2 (0.5) 100.0 % -0.15 [ -0.47, 0.17 ]
Subtotal (95% CI) 13 13 100.0 % -0.15 [ -0.47, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
-4 -2 0 2 4
Favours control Favours treatment
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Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training vs control in Charcot-Marie-Tooth disease
Outcome: 3 Change in time spent to achieve mobility activities (seconds)
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
4 standing up from lying supine (seconds)
Lindeman 1995 13 0.1 (0.5) 13 0.3 (0.6) 100.0 % -0.20 [ -0.62, 0.22 ]
Subtotal (95% CI) 13 13 100.0 % -0.20 [ -0.62, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
-4 -2 0 2 4
Favours control Favours treatment
A P P E N D I C E S
Appendix 1. OVID MEDLINE search strategy
1. ((foot adj1 drop$3) or floppy foot).mp. or drop foot/
2. exp gait disorders, neurologic/
3. (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp
4. leg/ or foot/ or ankle/ or achilles tendon/ or tendon injuries/ or peroneal nerve/ or ankle injuries/ or foot injuries/ or foot deformities,
acquired/
5. ((lower adj2 motor neuron$2) or motorneuron$2).mp
6. contracture$.mp
7. Contracture/
8. dorsiflex$.mp
9. neuromuscular$ disease$.mp]
10. exp Neuromuscular Diseases/
11. nerve compression syndromes/
12. nerve compression syndromes.mp
13. exp peripheral nervous system diseases/
14. peripheral$ nervous$ system$ disease$.mp
15. rehabilitation$.mp
16. activities of daily living.mp
17. exercise/
18. exercise.mp
19. (physical therap$ or physiotherap$ or physical stimulation$).mp
20. SURGERY/ or surgery.mp
21. ORTHOTIC DEVICES/
22. orthotic$.mp
23. orthos$.mp
24. Splints/
25. splint$.mp
26. exp REHABILITATION/
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27. or/9-14
28. or/15-25
29. 3 or 4
30. 6 or 7 or 8
31. 29 and 30
32. 1 or 2 or 5 or 31
33. 27 and 32
34. 28 and 33
35. randomized controlled trial.pt.
36. randomized controlled trials/
37. controlled clinical trial.pt.
38. controlled clinical trials/
39. random allocation/
40. double-blind method/
41. single-blind method/
42. clinical trial.pt.
43. exp clinical trials/
44. (clin$ adj25 trial$).tw.
45. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy)).tw.
46. placebos/
47. placebo$.tw.
48. random$.tw.
49. research design/
50. (clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
51. multicenter study.pt.
52. meta analysis.pt.
53. Prospective Studies/
54. Intervention Studies/
55. Cross-Over Studies/
56. Meta-Analysis/
57. (meta?analys$ or systematic review$).tw.
58. control.tw.
59. or/35-58
60. Animal/
61. Human/
62. 60 and 61
63. 60 not 62
64. 59 not 63
65. 34 and 64
Appendix 2. OVID EMBASE search strategy
1. ((foot adj1 drop$3) or floppy foot).tw. or peroneus nerve paralysis/
2. exp locomotion/ or gait disorders/
3. (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).tw.
4. leg/ or foot/ or ankle/ or achilles tendon/ or tendon injury/ or peroneus nerve/ or ankle injury/ or foot injury/ or foot malformation/
5. ((lower adj2 motor neuron$2) or motorneuron$2).tw.
6. contracture$.tw.
7. Contracture/
8. dorsiflex$.tw.
9. neuromuscular$ disease$.tw.
10. exp Neuromuscular Diseases/
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11. nerve compression/
12. nerve compression syndromes.tw.
13. exp peripheral neuropathy/
14. peripheral$ nervous$ system$ disease$.tw.
15. rehabilitation$.tw.
16. activities of daily living.tw.
17. exercise/
18. exercise.tw.
19. (physical therap$ or physiotherap$ or physical stimulation$).tw.
20. SURGERY/ or surgery.tw.
21. ORTHOTICS/
22. orthotic$.tw.
23. orthos$.tw.
24. Splint/
25. splint$.tw.
26. exp REHABILITATION/
27. or/9-14
28. or/15-25
29. 3 or 4
30. 6 or 7 or 8
31. 29 and 30
32. 1 or 2 or 5 or 31
33. 27 and 32
34. 28 and 33
35. Randomized Controlled Trial/
36. Clinical Trial/
37. Multicenter Study/
38. Controlled Study/
39. Crossover Procedure/
40. Double Blind Procedure/
41. Single Blind Procedure/
42. exp RANDOMIZATION/
43. Major Clinical Study/
44. PLACEBO/
45. Meta Analysis/
46. phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
47. (clin$ adj25 trial$).tw.
48. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
49. placebo$.tw.
50. random$.tw.
51. control$.tw.
52. (meta?analys$ or systematic review$).tw.
53. (cross?over or factorial or sham? or dummy).tw.
54. ABAB design$.tw.
55. or/35-54
56. human/
57. nonhuman/
58. 56 or 57
59. 55 not 58
60. 55 and 56
61. 59 or 60
62. 34 and 61
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Appendix 3. OVID CINAHL search strategy
1. ((foot adj1 drop$3) or floppy foot).mp
2. exp locomotion/
3. (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp
4. leg/ or foot/ or ankle/ or achilles tendon/ or tendon injury/ or peroneus nerve/ or ankle injury/ or foot injury/ or foot malformation/
5. ((lower adj2 motor neuron$2) or motorneuron$2).mp. [mp=title, subject heading word, abstract, instrumentation]
6. contracture$.mp
7. Contracture/
8. dorsiflex$.mp
9. neuromuscular$ disease$.mp
10. exp Neuromuscular Diseases/
11. nerve compression syndromes/
12. nerve compression syndromes.mp
13. exp peripheral nervous system diseases/
14. peripheral$ nervous$ system$ disease$.mp
15. rehabilitation$.mp.
16. activities of daily living.mp
17. exercise/
18. exercise.mp
19. (physical therap$ or physiotherap$ or physical stimulation$).tw.
20. surgery, operative/ or surgery.mp
21. exp orthoses/
22. orthotic$.mp
23. orthos$.mp
24. Splints/
25. splint$.mp
26. exp REHABILITATION/
27. or/9-14
28. or/15-25
29. 3 or 4
30. 6 or 7 or 8
31. 29 and 30
32. 1 or 2 or 5 or 31
33. 27 and 32
34. 28 and 33
35. random assignment/ or random sample/ or simple random sample/ or stratified random sample/ or systematic random sample/
36. Crossover design/
37. exp Clinical trials/
38. Double-blind studies/ or triple blind studies/
39. Placebos/
40. Quasi-experimental studies/
41. Solomon four-group design/ or Static group comparison/
42. Meta analysis/
43. Concurrent prospective studies/ or Prospective studies/
44. Factorial design/
45. (”clinical trial“ or ”systematic review“).pt.
46. random$.tw.
47. ((Single$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
48. (cross?over or placebo$ or control$ or factorial or sham? or dummy).tw.
49. ((clin$ or intervention$ or compar$ or experiment$ or preventive or therapeutic) adj10 trial$).tw.
50. ABAB design$.tw.
51. (meta?analys$ or systematic review$).tw.
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52. or/35-51
53. 52 and 34
Appendix 4. OVID AMED search strategy
1. ((foot adj1 drop$3) or floppy foot).mp. [mp=abstract, heading words, title]
2. gait/ or locomotion/ or movement/
3. (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp. [mp=abstract, heading words, title]
4. leg/ or foot/ or ankle/ or achilles tendon/ or tendon injuries/ or peroneal nerve/ or ankle injuries/ or foot injuries/ or foot deformities,
acquired/
5. ((lower adj2 motor neuron$2) or motorneuron$2).mp. [mp=abstract, heading words, title]
6. contracture$.mp. [mp=abstract, heading words, title]
7. Contracture/
8. dorsiflex$.mp. [mp=abstract, heading words, title]
9. neuromuscular$ disease$.mp. [mp=abstract, heading words, title]
10. exp Neuromuscular Disease/
11. nerve compression syndromes/
12. nerve compression syndromes.mp. [mp=abstract, heading words, title]
13. exp peripheral nervous system disease/
14. peripheral$ nervous$ system$ disease$.mp. [mp=abstract, heading words, title]
15. rehabilitation$.mp. [mp=abstract, heading words, title]
16. activities of daily living.mp. [mp=abstract, heading words, title]
17. exercise/
18. exercise.mp. [mp=abstract, heading words, title]
19. (physical therap$ or physiotherap$ or physical stimulation$).mp. [mp=abstract, heading words, title]
20. SURGERY/ or surgery.mp. [mp=abstract, heading words, title]
21. ORTHOTIC DEVICES/
22. orthotic$.mp. [mp=abstract, heading words, title]
23. orthos$.mp. [mp=abstract, heading words, title]
24. Splints/
25. splint$.mp. [mp=abstract, heading words, title]
26. exp REHABILITATION/
27. or/9-14
28. or/15-25
29. 3 or 4
30. 6 or 7 or 8
31. 29 and 30
32. 1 or 2 or 5 or 31
33. 27 and 32
34. 28 and 33
35. Randomized controlled trials/
36. Random allocation/
37. Double blind method/
38. Single-Blind Method/
39. exp Clinical Trials/
40. (clin$ adj25 trial$).tw.
41. ((singl$ or doubl$ or treb$ or trip$) adj25 (blind$ or mask$ or dummy)).tw.
42. placebos/
43. placebo$.tw.
44. random$.tw.
45. research design/
46. Prospective Studies/
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47. cross over studies/
48. meta analysis/
49. (meta?analys$ or systematic review$).tw.
50. control$.tw.
51. (multicenter or multicentre).tw.
52. ((study or studies or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).tw.
53. or/35-52
54. 34 and 53
Appendix 5. BNI search strategy
1. ((foot adj1 drop$3) or floppy foot).mp
2. mobility/
3. (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp
4. exp foot care/ and disorders/
5. ((lower adj2 motor neuron$2) or motorneuron$2).mp
6. contracture$.mp
7. Contracture/
8. dorsiflex$.mp
9. neuromuscular$ disease$.mp
10. exp Neuromuscular system/ and disorders/
11. nerve compression syndromes/
12. nerve compression syndromes.mp
13. exp peripheral nervous system diseases/
14. peripheral$ nervous$ system$ disease$.mp.
15. rehabilitation$.mp
16. activities of daily living.mp
17. physical fitness/
18. exercise.mp
19. (physical therap$ or physiotherap$ or physical stimulation$).tw.
20. surgery, operative/ or surgery.mp
21. orthopaedic devices/
22. orthotic$.mp
23. orthos$.mp
24. splint$.mp
25. exp REHABILITATION/
26. or/9-14
27. or/15-25
28. 3 or 4
29. 6 or 8
30. 28 and 29
31. 1 or 2 or 5 or 30
32. 26 and 31
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